TB

This report presents summary data for U.S. TB cases reported to the Division of TB Elimination, CDC, during 2015.

This fact sheet provides an overview of treating TB disease in persons infected with HIV/AIDS.

This document describes the steps necessary to implement the shorter regimen and the new drugs for drug-resistant TB treatment, including diagnosis and bacterial confirmation of drug resistance, treatment regimen design, monitoring of treatment efficacy and safety, and programmatic evaluation.

The Latent TB Infection (LTBI) Treatment Fact Sheet Series is designed to complement patient education delivered by healthcare professionals. Each sheet provides patients with a written reminder of their treatment regimen, medication side effects, actions to take if side effects do occur, tips to help remain adherent to the medication, and instructions in the event a dose of medication is missed.

This brochure describes Mycobacterium bovis (bovine tuberculosis) in humans and in cattle.

WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This report is updated annually.

The New York City Health Code requires all health care providers to submit a written TB Treatment Plan to the New York City Department of Health & Mental
Hygiene (DOHMH) within one month of starting treatment for newly diagnosed TB patients.

This report provides surveillance data, concise summaries of core program activities, and highlights for 2015.

This hospital discharge approval request form is required in New York City as New York City Health Code mandates health care providers to obtain approval
from the New York City Department of Health & Mental Hygiene (DOHMH) before discharging infectious TB patients from the hospital.

This report analyses the factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. Detailed pricing profiles of key DR-TB drugs are also provided.